REFERENCES
1. O'Leary M, Krailo M, Anderson JR, Reaman GH; Children's Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008;35:484-93.
2. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012;120:2807-16.
3. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14:e205-17.
4. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hahlen K, Gobel U, Klingebiel T, Ludwig WD, Henze G. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005;23:7942-50.
5. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012;120:1165-74.
6. Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, Condos G, Hunger SP, Raetz E, Saffery R, Relling MV, Bhojwani D, Morrison DJ, Carroll WL. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011;118:5218-26.
7. Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S. CD22 Exon 12 deletion as a novel pathogenic mechanism of human B-precursor leukemia. Proc Natl Acad Sci U S A 2010;107:16852-7.
8. Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Br J Haematol 2012;156:89-98.
9. Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule. Integr Biol (Camb) 2015;7:237-49.
10. Uckun FM, Qazi S, Ma H, Yin L, Cheng J. A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies. EBioMedicine 2014;1:141-55.
11. Uckun FM, Ma H, Cheng J, Myers DE, Qazi S. CD22ΔE12 as a molecular target for RNAi therapy. Br J Haematol 2015;169:401-14.
12. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125-34.
13. van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122:2622-9.
14. Uckun FM, Qazi S, Cheng J. Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles. Future Oncol 2015;11:1149-52.
15. Zheng N, Song Z, Liu Y, Zhang R, Zhang R, Yao C, Uckun FM, Yin L, Cheng J. Redox-responsive, reversibly-crosslinked thiolated cationic helical polypeptides for efficient siRNA encapsulation and delivery. J Control Release 2015;205:231-9.
16. He H, Zheng N, Song Z, Kim KH, Yao C, Zhang R, Zhang C, Huang Y, Uckun FM, Cheng J, Zhang Y, Yin L. Suppression of hepatic inflammation via systemic siRNA delivery by membrane-disruptive and endosomolytic helical polypeptide hybrid nanoparticles. ACS Nano 2016;10:1859-70.
17. Uckun FM, Mitchell LG, Qazi S, Liu Y, Zheng N, Myers DE, Song Z, Ma H, Cheng J. Development of polypeptide-based nanoparticles for non-viral delivery of CD22 RNA trans-splicing molecule as a new precision medicine candidate against B-lineage ALL. E Bio Medicine 2015;2:649-59.
18. D'Cruz OJ, Uckun FM. Novel monoclonal antibody-based therapies for leukemia. In: Monoclonal Antibodies in Oncology. London: Future Medicine Ltd; 2013. pp. 54-77.
19. Uckun FM, Sun L, Qazi S, Ma H, Ozer Z. Recombinant human CD19-ligand protein as a potent anti-leukemic agent. Br J Haematol 2011;153:15-23.
20. Uckun FM, Myers DE, Qazi S, Ozer Z, Rose R, D'Cruz OJ, Ma H. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. J Clin Invest 2015;125:1006-18.
